Literature DB >> 15918989

Perception of risk: the state of COX-2 selective inhibitors.

Lee S Simon1, Vibeke Strand.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15918989     DOI： 10.1007/s11926-996-0032-4

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  22 in total

Review 1.  Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity.

Authors:  Maarten Boers; Ben Dijkmans; Sherine Gabriel; Hilal Maradit-Kremers; James O'Dell; Theodore Pincus
Journal:  Arthritis Rheum       Date:  2004-06

2.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

3.  Risk perception of prescription drugs: report on a survey in Canada.

Authors:  P Slovic; N Kraus; H Lappe; M Major
Journal:  Can J Public Health       Date:  1991 May-Jun

4.  Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Authors:  A Whelton; J G Fort; J A Puma; D Normandin; A E Bello; K M Verburg
Journal:  Am J Ther       Date:  2001 Mar-Apr       Impact factor: 2.688

5.  Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.

Authors:  M A Konstam; M R Weir; A Reicin; D Shapiro; R S Sperling; E Barr; B J Gertz
Journal:  Circulation       Date:  2001-11-06       Impact factor: 29.690

6.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

7.  Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.

Authors:  Mary F Walter; Robert F Jacob; Charles A Day; Rachel Dahlborg; Yujia Weng; R Preston Mason
Journal:  Atherosclerosis       Date:  2004-12       Impact factor: 5.162

8.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.

Authors:  Daniel H Solomon; Robert J Glynn; Raisa Levin; Jerry Avorn
Journal:  Arch Intern Med       Date:  2002-05-27

9.  Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

Authors:  William B White; Gerald Faich; Andrew Whelton; Clement Maurath; Nancy J Ridge; Kenneth M Verburg; G Steven Geis; James B Lefkowith
Journal:  Am J Cardiol       Date:  2002-02-15       Impact factor: 2.778

10.  Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

Authors:  Daniel H Solomon; Sebastian Schneeweiss; Robert J Glynn; Yuka Kiyota; Raisa Levin; Helen Mogun; Jerry Avorn
Journal:  Circulation       Date:  2004-04-19       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.